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Purpose: This consensus statement from the Breast Cancer Working Group of Groupe Européen de
Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO) aims at generating prac-
tical guidelines for multi-catheter image-guided brachytherapy in the conservative management of
breast cancer patients used for either Accelerated Partial Breast Irradiation (APBI) or for a breast boost.
Methods: Recent advances in techniques of multi-catheter brachytherapy were summarized and all the
relevant literature was reviewed by a panel of experts. Panel members of the GEC-ESTRO experts partic-
ipated in a series of conferences, supplemented their clinical experience, were surveyed to determine
their current practices and patterns, performed a literature review, and formulated recommendations
for implementing APBI with multi-catheter brachytherapy, focusing on treatment planning issues, cathe-
ter insertion, dosimetry and quality assurance. This document was reviewed and approved by the full
panel, the GEC-ESTRO executive board and by the ACROP (Advisory Committee on Radiation Oncology
Practice).
Results: Three-dimensional (3D) treatment planning, catheter insertion techniques, dosimetry and meth-
ods of quality assurance for APBI and boost with multi-catheter image-guided brachytherapy after breast
conserving surgery are described. Detailed recommendations for daily practice including dose constraints
are given.
Conclusions: Recent standards and guidelines for the use of APBI with different multi-catheter image-
guided brachytherapy techniques have been defined. Different techniques are used to insert the cathe-
ters. Guidelines are mandatory to assure precise catheter insertion for coverage of the target volume
and to guarantee high-quality dosimetry. The same rules apply for brachytherapy based boost irradiation
for breast cancer after whole breast irradiation as well as for partial breast re-irradiation.
 2018 The Authors. Published by Elsevier B.V. Radiotherapy and Oncology xxx (2018) xxx–xxx This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Interstitial multi-catheter brachytherapy in the context of
breast conserving therapy (BCT) represents one of the most highly
published irradiation techniques for Accelerated Partial Breast Irra-
diation (APBI) alone, Salvage-APBI and Boost after whole breast
irradiation (WBI) [1–4]. Generally, this technique delivers a high-
dose to a precise, strictly limited in-breast target volume, avoiding
to the greatest possible extent, exposure of adjacent organs at risk(OARs) thus resulting in excellent local control with low rates of
side effects [1,5–12]. To date, APBI using multi-catheter
brachytherapy is the only method of breast irradiation with a
treatment duration of merely 4–5 days with level 1 evidence
showing it to be a valid treatment alternative to WBI after breast
conserving surgery (BCS) for low-risk breast cancer patients which
is used in clinical routine [1,4,9–12]. Sole APBI based on multi-
catheter brachytherapy is intended first to shorten treatment dura-
tion compared with the WBI regimen (40–50 Gy over 3–6 weeks)
and second to reduce late side effects to OARs such as the heart,Breast
.1016/j.
2 ESTRO-ACROP practical guidelinelung and skin while achieving similar rates of local control,
disease-free survival and overall survival. As a consequence, sole
APBI with multi-catheter brachytherapy is also a unique treatment
technique for re-irradiation after re-excision (Salvage-APBI, Accel-
erated Partial Breast Re-Irradiation – APBrI) after previous BCS and
WBI with an exceptionally low rate of side effects and with local
recurrence rates comparable to salvage mastectomy alone [2].
Recently, guidelines for patient selection and target definition
for APBI after both breast conserving closed and open cavity sur-
gery as well as dose recommendations according to risk factors
were provided by the Breast Cancer Working Group of GEC-
ESTRO [13–15]. Similar guidelines for patient selection were also
published by numerous USA societies [16–18]. Guidelines for treat-
ment planning using different techniques for APBI were provided
by the National Surgical Adjuvant Breast and Bowel Project
(NSABP) B-39/Radiation Therapy Oncology Group (RTOG) 0413
Protocol [19]. The NSABP B-39 protocol included criteria for target
coverage as well as for sparing OARs.
The aim of this consensus statement of the GEC-ESTRO Breast
Cancer Working Group is to generate detailed practical guidelines
for APBI, boost after WBI or APBrI with multi-catheter image-
guided brachytherapy for the conservative management of breast
cancer patients in daily practice.Methods
The authors evaluated the relevant literature, identified estab-
lished and controversial topics via working conferences, circular
emails, meetings, conference calls and supplemented this informa-
tion with their clinical experience to formulate the current guide-
lines. A consensus decision was made to incorporate strategies
using 3D image guidance for interstitial brachytherapy based APBI.
Specific commercial equipment, instruments, and materials are
described only when necessary. Such identification does not imply
recommendation or endorsement by the presenter nor imply that
the identified material or equipment is necessarily the best avail-
able for these purposes.
This report document was reviewed and approved by the full
panel, the GEC-ESTRO executive board and by ACROP.Results
Technical recommendations
General issues related to multi-catheter HDR-/PDR-brachytherapy
We recommend that APBI with image-guided multi-catheter
brachytherapy after breast conserving surgery (BCS) should be
completed preferably in less than 12 weeks and no longer than
20 weeks, as better local tumour control and survival can probably
be expected than with a longer time frame [20–27]. Nevertheless a
recent analysis illustrated that starting of radiation therapy shortly
after BCS seems not to be associated with a better long-term out-
come [28]. In Europe, the most common HDR-brachytherapy regi-
men used for APBI prescribes 2 fractions per day for a total of 7–10
fractions.
Patient selection for APBI alone after BCS in patients with early
breast cancer should be performed according to the GEC-ESTRO- or
the ASTRO guidelines [13,29]. The GEC-ESTRO panel of members
holds the view that until the results of the NSABP B-39/RTOG
0413 APBI trial are available, GEC-ESTRO selection criteria should
remain unchanged, particularly because current published data
of phase 3 trials [1,11,30–33] so far do not allow one to analyse
corresponding subgroups of interest. As far as patient selection cri-
teria for APBrI, we suggest using the criteria as published by
Hannoun-Levi et al. [2]. Furthermore we advise using criteria asPlease cite this article in press as: Strnad V et al. ESTRO-ACROP guideline: Int
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[34–38].
Furthermore we advise defining the target in accordance with
current published guidelines [14,15].
Treatment planning and catheter insertion
Pre-implant treatment planning may be performed either in a
separate procedure as in a pre-plan approach, or on the day of
the procedure in the operating room as intra-operative preplan-
ning. Whatever the pre-implant treatment planning and mode of
catheter insertion as listed below, the following information must
be available at the time of preplanning and at the time of catheter
insertion: surgical report, pathological report including size of
resection margins in 6 directions, knowledge about number and
position of surgical clips, images of preoperative mammography,
ultrasound and, if necessary, magnetic resonance imaging (MRI).
The standard procedure for catheter insertion is to use a tran-
scutaneous approach usually in week 4 to 12–20 after BCS under
computed tomography (CT) or ultrasound (US) or X-ray monitoring
and template guidance (if needed). According to the Paris System, a
square or triangular arrangement is reasonable [39]. Boost
brachytherapy should follow WBI as soon as possible within 4
weeks depending on the extent and grade of skin inflammation
after WBI. Patient positioning should coincide with the pre-
implant planning study as closely as possible when a preplan
approach is used. If US equipment is used a high-resolution system
is recommended. When the surgeon leaves the cavity open, the
seroma can easily be identified during needle insertion [40], and
thus the needles cover the shape of the cavity (Image-guided
Brachytherapy). After closed cavity surgery, a pre-implant CT with
radiopaque marks on the skin scar and nipple is useful in order to
locate the surgical scar and/or the clips. If no clips are in place and
a surgical scar cannot be identified, a CTV is difficult to define so an
APBI or boost cannot be easily and securely performed. Fluo-
roscopy (as X-ray based guidance) as a complementary imaging
modality can only be used if surgical clips are present.
CT-based pre-implant treatment planning and insertion of catheters
after open cavity surgery
According to timing and number of CT imaging, various policies
exist, but the catheter positions are always determined using the
3D rendering of the target volume and patient anatomy. Planning
the catheter positions can be done using a plastic template on
the breast during pre-implant CT imaging [41,42]. Then, using 3D
rendering of patient anatomy and virtual simulation the appropri-
ate catheter positions can be defined. A few needles (e.g. in deep
plane – close to the thoracic wall) can be inserted freehand, and
the remainder with a template. The template is made of plastic;
it has two plates with holes arranged in regular geometry with a
triangular pattern. The distance between the holes is between 12
and 20 mm (Fig. 1). Ideally, two CT image series (pre-implant
and post-implant) are used for the implantation and treatment
planning [41,42]. First, one day before implantation a CT-
compatible plastic template is placed over the breast skin taking
into account the scar position on the skin and other relevant clin-
ical information about the tumour location. Distance between the
template plates is recorded and their positions are marked on
the skin. Pre-implant CT imaging is performed, the cavity is out-
lined in axial slices, and the target volume is created according
to the contouring protocol. Using 3D rendering in the treatment
planning system, the patient’s image data are then rotated to the
‘‘needle’s eye view”, i.e. viewing in the direction of the needles,
and the target volume is projected on to the rendered template
with the holes (Fig. 2). By visual inspection the holes covering
the target volume are identified, and their coordinates are
recorded. On the following day, another more rigid template,erstitial multi-catheter breast brachytherapy as Accelerated Partial Breast
tical recommendations. Radiother Oncol (2018), https://doi.org/10.1016/j.
Fig. 1. Template-based insertion of needles and replacement with plastic catheters.
Fig. 2. Three-dimensional rendering of patient surface and template in needle’s eye
view showing the target volume projected to one of the plates of the template.
V. Strnad et al. / Radiotherapy and Oncology xxx (2018) xxx–xxx 3which is geometrically identical to the first one, is placed in the
same position as the day before using the skin marks and template
parameters as guides. Then, using the predefined coordinates the
needles are inserted into the breast and later replaced with plastic
catheters. Another CT data set is acquired for treatment planning
and the target volume definition with organs at risk [14,15]. Where
no appropriate target coverage is detected, a few additional cathe-
ters should be implanted by free hand – without use of a template.
Obviously, in this case new CT imaging is required for planning.Fig. 3. Pre-implant virtual vectors in order to cover properly the PTV.CT-based pre-implant treatment planning and catheter insertion after
closed cavity surgery
In case of closed-cavity surgery, the pre-implant CT-scanning
procedure is the same as in the open cavity situation presented
above. While the target volume is outlined and checked in the
three main views (axial, coronal and sagittal), the physician places
virtual vectors in order to cover the target volume properly leaving
12–20 mm between vectors and planes (Fig. 3). Then, the virtual
implant 3D reconstructions, including sagittal and frontal views,
are printed (with specific measures helping vector placement);
specific breast skin marks are drawn at the entry and exit points
of vector placement (Fig. 4).Ultrasound based pre-implant treatment planning and catheter
insertion after open cavity surgery
Before brachytherapy, all patients should undergo a CT scan to
identify the surgical bed, the clips [14,15] and, in an open cavityPlease cite this article in press as: Strnad V et al. ESTRO-ACROP guideline: Int
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first to inject the radiological contrast agent (dilute barium) into
the existing surgical cavity, so that it is easy to identify this cavity
any time with US, CT or X-ray. When inserting metal implant nee-
dles, we recommend using US to check each needle position in
relation to the seroma. The deepest implant plane should be dorsal
the seroma and the most ventral between the skin and the seroma.
Special care must be taken that the needles are positioned at a dis-
tance of at least 1 cm from the skin to avoid late skin side effects.
When the seroma is completely surrounded by needles, the nee-
dles are replaced by plastic catheters and the insertion procedure
is finished. Finally, the symmetry and parallelism of the implant
should be checked with the US probe.erstitial multi-catheter breast brachytherapy as Accelerated Partial Breast
tical recommendations. Radiother Oncol (2018), https://doi.org/10.1016/j.
Fig. 4. 3D reconstructions of the virtual implant used before vector placement.
4 ESTRO-ACROP practical guidelineUltrasound based pre-implant treatment planning and catheter
insertion after closed cavity surgery
After closed cavity surgery it is not easy to detect the surgical
bed with US. Nevertheless it is often possible to visualize some
areas of the surgical scar that can be seen as white tracts instead
of the dark normal lobular structure of the breast (Fig. 5). As
opposed to this chest wall and ribs are easily identified. Before
catheter insertion a clinical assessment of the CTV-position isFig. 5. US view in a closed cavity case, with three plastic tubes and a white area
corresponding to the absence of lobular normal tract due to the surgical scar. The
chest wall is also well defined.
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with the help of cranio-caudal and oblique mammograms consid-
ering the relative distance to the nipple, and the description by
the surgeon. The implant depth and plane levels should be chosen
while inserting the needles. The distance of needles to the skin can
be measured steadily taking care not to press too hard on the skin
with the probe. Before the insertion of the first implant needle, the
estimated position and area of CTV must be projected and drawn
on the skin and also visualized continual with US to confirm appro-
priate, precise and definitive implant volume.
X-ray based pre-implant treatment planning and catheter insertion
after closed cavity surgery
An important precondition for X-ray guided catheter insertion
is, that the resection margins of the surgical bed inside the breast
are labelled with surgical marker clips (at least 4, ideally 6 clips),
which are easily distinguished with a C-arm X-ray-device or with
CT.
With simultaneous consideration of the surgical scar on the skin
and of the deepest part of the surgical scar inside the breast (sur-
gical clips), the radiation oncologist can project the surgical bed
on to the skin and define the target volume inside the breast.
The first step in the insertion of plastic catheters is the insertion
of the guide needle (Fig. 6). The insertion point of the first (guide)
needle and desired direction of the insertion should first be marked
on the skin (CT- or C-arm guided) and should guarantee that the
position of the guide needle corresponds to the deepest point dor-
sal the centre of the surgical bed. The guide needle usually repre-
sents the centre of the deepest plane of the whole implant. In
addition, during this first step as well as during the whole insertion
procedure, it is important to take into account not only the position
of the clips the surgical scar inside the breast and the skin scar but
also the location of the tumour inside the breast as shown in the
preoperative imaging. After insertion of the guide needle, we rec-
ommend that a template of appropriate size is taken over the guide
needle in order to guarantee that all the following needles will be
inserted parallel and equidistant to the guide needle, which makes
it easier to meet quality parameters. The appropriate size of the
template also allows the tumour bed and the surgical scar inside
the breast to be encompassed with an adequate safety margin
[14] in all directions. An acceptable alternative is free-hand inser-
tion of catheters (without template) which is safe in experienced
hands. Thus, the corresponding number of needles will be
implanted, the position of needles in relation to the surgical scar
verified with CT or C-arm and as a final step the needles are
replaced by plastic catheters (Fig. 1).
Intraoperative insertion of catheters
Here the surgical bed is well defined, because the cavity is at
time of catheter insertion still open and the surgeon or the radia-
tion oncologist can point to the exact former position of the
removed tumour to insert the first catheter. The catheters are
inserted immediately as the lumpectomy is performed. Metal clips
(cranial, caudal, ventral, dorsal, medial, lateral) mark the surgical
bed, that is, the area of the tissue removed by the surgeon.
Although the tumour location inside of surgical bed can be eccen-
tric, the perioperative procedure allows consider exactly this fact.
As consequence the central needle should be considered as the ref-
erence needle to define the position of the tumour bed (‘‘guide
needle”). All needles can be inserted using a template or free-
hand as the surgical cavity is still open, or the surgeon can close
the cavity and skin after inserting the ‘‘guide needle”. The next par-
allel needles are inserted to create the 2–3 planes around the
guide-needle. As soon as the insertion of all needles is finished,
the needles are replaced by plastic catheters, and secured on both
sides with buttons.erstitial multi-catheter breast brachytherapy as Accelerated Partial Breast
tical recommendations. Radiother Oncol (2018), https://doi.org/10.1016/j.
Fig. 6. X-ray based insertion of guide needle.
V. Strnad et al. / Radiotherapy and Oncology xxx (2018) xxx–xxx 5The CT planning is done the next day. Treatment can be initi-
ated once the pathology report (usually the same day or 2–3 days
after surgery) is available. A good collaboration with the patholo-
gist allows keeping the total number of days the catheters remain
implanted to a minimum. If multi-catheter brachytherapy is used
as a boost with this perioperative method, the treatment can start
on the same day.
Treatment with rigid needles
The interstitial multi-catheter technique was used for a many
years in selected cases of breast carcinoma to deliver a boost dose
by means of rigid needles with LDR Iridium-192 wires [43–45]. The
calculation of the dose and dosimetry was based on isodose curves
according to the Paris system, without an image-related target vol-
ume [39]. Clinical assessment of the tumour bed and location of
clips and needles using only an X-ray C-arm is now standard.
The use of needles instead of plastic tubes is a matter of tolerance
by the patient during a treatment that lasts at least four days. In
these cases, the homogeneity that can be achieved with parallel
needles is very high and this allows increasing the total dose and
dose per fraction (HDR-brachytherapy).
Catheter reconstruction
Since the dose distribution depends on the source dwell posi-
tions in the catheters, their 3D arrangement must be known. As a
first step, the catheters have to be reconstructed in space using
cross-sectional imaging. CT is the recommended imaging method
for treatment planning including catheter reconstruction. Using a
slice thickness of 3 mm or less is recommended. As dwell times
inside the catheters will vary, clear and unequivocal catheter num-
bering (on the CT data set) and labelling (of the real catheters) isPlease cite this article in press as: Strnad V et al. ESTRO-ACROP guideline: Int
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planning data are transferred to the control unit of the afterloading
machine. For better visualization, special markers can be inserted
into the catheters before imaging, but in most cases the internal
air in the catheters can be a surrogate for the markers, and with
proper windowing, the reconstruction can be properly performed.
The CT-marker can show the first possible dwell position in the
catheter, but the equivalence of the planned and real source posi-
tions must be known and has to be verified – at least once or peri-
odically - by measurement. When markers are not used, the
fixation button at the distal end of each catheter must be visible
on the CT images, because the first possible dwell position has to
be related to it. The catheter reconstruction can be performed in
any of the main orthogonal planes (axial, sagittal, and coronal).
Furthermore, oblique planes parallel with, or orthogonal to, the
catheters can be created in many TPSs by defining an extra coordi-
nate system (ECS) which helps in the reconstruction process. Hav-
ing reconstructed all possible source dwell positions, the actual
active source length must be determined. This is done taking into
account the expansion of the PTV and OAR structures. In the first
step, active source positions could be set within the PTV (from sur-
face to surface). The final arrangement of active source positions
depends on the type of optimization and ultimately the resulting
dose distribution and DVH values. If needed, the active lengths
can extend beyond the PTV by a few mms.
Normalization of dose distribution, dose specification and prescription
In order to select an appropriate isodose for which a certain
absolute dose value should be prescribed, the dose distribution
has to be uniquely normalized. For a reproducible normalization
procedure, we recommend distributing four to ten dose referenceerstitial multi-catheter breast brachytherapy as Accelerated Partial Breast
tical recommendations. Radiother Oncol (2018), https://doi.org/10.1016/j.
6 ESTRO-ACROP practical guidelinepoints in the central implant plane midway between the active
source positions in the regions where the dose gradient has a local
minimum. As the gradient varies with the source dwell time during
the optimization process, the actual positions of individual refer-
ence points can be corrected slightly during the planning process.
The initial dose distribution is normalized to the mean dose in the
reference points (corresponding approximately to the mean central
dose (MCD) in ICRU 58 [48]). After specification of the prescribed
dose on an isodose line between 80 to 90% of the mean dose at
the reference points, the dose distribution is renormalized, and
as a consequence the 100% isodose corresponds to the prescribed
dose (PD).
Alternatively, in case of an inverse optimization the prescribed
absolute dose by default is set to the 100% isodose. The dwell times
are calculated on the basis of volumetric dosimetric constraints,
with preset goals defined in the objectives like target coverage,
dose homogeneity and dose to OAR-s.
Dose optimization methods
Dose optimization means the determination of individual dwell
time in each dwell position in order to get an optimal dose distri-
bution regarding target coverage, sparing of OARs and dose homo-
geneity. Dose optimization methods help to improve dose
distribution, but it has to be stressed that no optimization can
compensate for poor implant geometry. The aims of any optimiza-
tion method can be summarized as follow:
– to get an appropriate dose coverage of the PTV with a conformal
dose distribution,
– to achieve to some extent a homogeneous dose distribution
inside the implant,
– to keep the dose to OARs as low as possible, or at least below the
corresponding tolerance doses,
– to keep high-dose volumes below certain absolute values.
Optimization methods can be categorized to forward and
inverse techniques. The simplest forward optimization is the man-
ual editing of the dwell times. Since this is rather time consuming, it
is recommended only for small local adjustments. A very popular
method is called geometrical optimization (GO) which results in a
homogeneous dose distribution. Provided that the catheters geo-
metrically cover the target volume properly, the target coverage
by the reference dose will also be acceptable. To change the shape
of isodoses locally or globally, graphical optimization (GRO) can be
used during which a selected isodose line can be shifted into the
desired position with the ‘‘drag and drop” function using a com-
puter mouse. The target coverage and conformity can be improved
with GRO but it must not be forgotten that at the same time the
homogeneity may deteriorate. In many clinical cases the GO fol-
lowed by GRO results in an acceptable dose distribution. After
usage of GRO the dwell times should be checked so as to avoid high
gradients in the dwell time distributions. Another forward opti-
mization method is the so-called polynomial optimization using
pre-defined dose points. However, dose homogeneity is not taken
into account during this optimization, therefore its use is not rec-
ommended. As all of these optimization methods are part of for-
ward planning, the influence on DVH parameters of target
volume and OAR-s has to be verified. Recently, inverse optimization
(IO) algorithms have become available with commercial BT plan-
ning systems. The great advantage of inverse optimization is that
all dosimetric requirements (dose coverage, dose homogeneity
and protection of organs at risk) are simultaneously and automat-
ically taken into account during the optimization. Before its use,
volume and surface based clinical objectives have to be defined.
However, the requirements for target coverage, dose homogeneity
and sparing of OARs are often conflicting, therefore finding thePlease cite this article in press as: Strnad V et al. ESTRO-ACROP guideline: Int
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needs some planning experience. Another benefit of inverse IO is
that it is user-independent and typically faster than a manual
approach.
Dose recommendation for multicatheter HDR-/PDR-brachytherapy
The radiobiology of HDR/PDR-brachytherapy and the use of the
linear-quadratic model to convert HDR to LDR doses were previ-
ously described and discussed in detail particularly for HDR/PDR-
brachytherapy of cervical carcinoma and prostate carcinoma [46–
50] and as a result, can be used in a similar way for breast
brachytherapy. It should be emphasized that because of the com-
plexity of all biological processes, these radiobiological calcula-
tions are approximations only, but can be used as a tool to make
comparisons between different fractionations, for example in
HDR brachytherapy where dose per fraction can deviate a lot from
the conventional 2 Gy.
The recommended schedules for APBI/APBrI with HDR-Brachytherapy
The schedules for HDR-brachytherapy based APBI, validated in a
randomized trial [1,4] are 8  4 Gy and 7  4.3 Gy scheduled 2
times per day, with an interval between fractions of at least 6 h,
and with a total treatment time of 4–5 days.
Other fractionations can be used. Nonetheless we recommend
that the chosen fractionation corresponds to a biologically equiva-
lent total dose EQD2 (a/b = 4–5 Gy) in the range of 42–45 Gy.
The recommended schedules for boost with HDR-Brachytherapy
A biologically equivalent total dose (EQD2 for a/b = 4–5 Gy) in
the range of 10–20 Gy in 1 to 4 fractions should be selected accord-
ing to current recommendations [37].
The panel of experts recommends preferably 2  4–6 Gy, or 3 
3–5 Gy scheduled 2 times per day, with an interval between frac-
tions of at least 6 h, and a total treatment time of 1–2 days, or a sin-
gle fraction of 7–10 Gy, depending on the desired total EQD2.
The recommended schedules for APBI/APBrI with PDR-Brachytherapy
Pulsed-dose 0.5–0.8 Gy/pulse, total dose 50 Gy, scheduled every
hour, 24 h per day, total treatment time 4–5 days.
The recommended schedules for boost with PDR-Brachytherapy are
Pulsed-dose 0.5–0.8 Gy/pulse, total dose 10–20 Gy [37], sched-
uled every hour, 24 h per day, total treatment time 1–2 days.
Dose–volume parameters and dose constraints
For an objective assessment of any treatment plan, quantitative
parameters have to be employed. Without taking into account any
outlined volumes, implant related dose volume parameters like the
volume that is irradiated by the prescribed dose (PD) (VPD) or 1.5
times the PD (V1.5xPD) can be calculated. The homogeneity of the
dose distribution is characterized with the ratio of the V1.5xPD to
VPD which is called the dose-non-uniformity ratio (DNR). The lower
the DNR, the more homogeneous dose distribution is. As a comple-
mentary index to DNR, dose homogeneity index (DHI) can also be
formulated. By definition, DHI = (VPD  V1.5xPD)/VPD that is DHI = 1
 DNR.
For outlined structures, additional parameters can be calcu-
lated. The percentage of the PTV receiving a given percentage of
the PD is generally used and denoted as Vxx. For example, V100
means percentage volume of the PTV receiving 100% dose of the
PD or more. To characterize high-dose volumes V150 and V200 are
calculated. The overdose volume index (OI) characterizes the dose
homogeneity using the volume irradiated by 2  PD, related to vol-
ume of the PTV. The coverage index (CI) is the fraction of the PTV
receiving at least the PD, and it is equal to V100/100. The conformal
index (COIN) takes into account the coverage of the PTV by the PDerstitial multi-catheter breast brachytherapy as Accelerated Partial Breast
tical recommendations. Radiother Oncol (2018), https://doi.org/10.1016/j.
Table 2
Recommended dose–volume limits for implant
and PTV.
Constraints
Implant VPD  300 cm3
DNR  0.35
PTV V100  90%
V150 < 65 cm3
V200 < 15 cm3
COIN  0.65
Table 3
Recommended dose–volume limits for OAR-s.
Organ Constraints
Ipsilateral non-target breast V90 < 10%
V50 < 40%
Skin* D1cm3 < 90%
D0.2cm3 < 100%
Rib D0.1cm3 < 90%
D1cm3 < 80%
Heart** MHD < 8%
D0.1cm3 < 50%
Ipsilateral lung MLD < 8%
D0.1cm3 < 60%
* Skin volume is defined as a 5 mm shell below the body
contour.
** Left sided lesion only, MHD: mean heart dose, MLD: mean
lung dose
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outside the PTV (PTVPD/VPD) [51]. PTVPD is the volume inside the
PTV irradiated by the PD and the VPD is the volume receiving at
least the PD. The dose distribution is at its most conformal when
the COIN is maximal and is as close to 1 as possible. Dose irradiat-
ing a certain part of the PTV is also used. Dxx means the relative
dose that irradiates xx% of the PTV. Depending on the type of the
OARs, mean dose, volume irradiated by a given relative dose (eg.
V5), absolute dose (eg. V5Gy), or dose irradiating a small volume
(eg. D0.1cm3, D2cm3) are generally reported. Regarding the skin, in
addition to the maximum surface point dose, reporting D0.2cm3 or
D1cm3 [52] is recommended. Table 1 lists the most common
dose–volume parameters used in interstitial breast brachytherapy.
In addition, on the post-implant CT-scan, the dose distribution
must be analysed in the 3 different views (axial, coronal and sagit-
tal) in order to verify the main dose constraints but also to avoid
the confluence of two consecutive V200 isodoses and a V200 isodose
diameter >10 mm [14,53–55].
Dose–volume limits for PTV and OARs
To date, no generally accepted criteria for a ‘‘good” breast
implant exist. In the GEC-ESTRO randomized trial the coverage
index (CI) had to be larger than 0.90, i.e., at least 90% of the PTV
had to receive the PD [56]. The NSABP B-39/RTOG protocol is more
lenient, since it requires that only 90% of the PD must cover 90% of
the PTV [19]. In the GEC-ESTRO study there was only one require-
ment for dose uniformity, namely the DNR < 0.35. According to the
experience of the centres participating in the GEC-ESTRO study and
respecting current available data [19,52,56,57] the recommended
dose–volume constraints for the implant, PTV and organs at risk
are presented in Tables 2 and 3. Since the dose to contralateral
breast and lung is low in interstitial brachytherapy, no threshold
is given for these organs, only a few parameters are recommended
for reporting.
Recommended parameters for reporting
The following data and parameters are recommended for treat-
ment reporting when using APBI, boost or APBrI with multi-
catheter brachytherapy:Table 1
The most common dose–volume parameters used for reporting in interstitial breast
brachytherapy.
Parameter Definition/calculation
Implant related
VPD Absolute volume irradiated by
the prescribed dose
V1.5xPD Absolute volume irradiated by
1.5 x the prescribed dose
DNR – dose non-uniformity ratio V1.5xPD/VPD
DHI – dose homogeneity index (VPD – V1.5xPD)/VPD
Target related
VPTV Volume of the PTV
Vxx Percentage of PTV receiving xx%
of the PD
OI – overdose volume index V2xPD/VPTV
CI – coverage index V100/100
COIN – conformal index PTVPD/VPTV  PTVPD/VPD
Dxx Percentage dose that covers xx%
of the PTV
OAR related
Dmean Mean dose in organ
VxGy Relative volume receiving  Gy
Vxx Percentage of organ receiving xx%
of the PD
Dxcm3 Relative dose given to most
exposed  cm3 of organ
PD: prescribed dose, PTVPD: volume in PTV received at least the PD.
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PDR).
2. Number of catheters used and number of implanted planes.
3. Method of dose optimization (manual, geometric, graphical,
inverse) and normalization (description of positions of the ref-
erence points).
4. Method of dose prescription (on isodose line, volumetric), dose
per fraction (pulse), total dose, and fractionation scheme with
time pattern.
5. Reference air kerma rate/source activity at the time of first
fraction.
6. Total reference air kerma (TRAK).
7. Implant related volume parameters: VPD, DNR.
8. Target related parameters: VPTV(cm3), V100, V150, V200, D90.
9. Optional OARs related parameters:
- ipsilateral non-target breast: V90, V50
- skin: D0.2cm3, D1cm3
- rib: D0.1cm3, D1cm3
- heart: MHD (mean heart dose), D0.1cm3
- ipsilateral lung: MLD (mean lung dose), D0.1cm3
- contralateral breast: D1cm3
- contralateral lung: D1cm3
Quality management issues for HDR-/PDR-brachytherapy
The use of HDR-/PDR-brachytherapy requires careful monitor-
ing and quality management (QM), given the potential for toxicity
andmisadministration [58]. Protocol consistency within an institu-
tion will help to avoid errors. Institutions should document the
insertion procedure, the planning parameters including normal-
tissue dose, the method of treatment, and follow-up. QM issues
common to all brachytherapy modalities, including treatment
planning systems, treatment delivery systems, applicator commis-
sioning, and periodic checks, will not be addressed in this docu-
ment. With the objective of preventing errors in treatmenterstitial multi-catheter breast brachytherapy as Accelerated Partial Breast
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following quality assurance procedures are recommended:
1. Check of treatment plan (before export to control unit)
a. Plan parameters
- Patient information (name, ID number, date of birth, can-
cer type),
- Dose prescription including fraction- (pulse-) dose and
number of fractions (pulses),
- Correspondence of first source dwell position to distal
catheter reconstruction point,
- Correct drive-out lengths depending on the type and
length of catheters (depends on
- afterloading system),
- Total reference air kerma (TRAK).b. Plan results
- A rough estimation of the calculated treatment time. This
could be done by comparing with the results of similar
plans or by creating a set of implant specific ‘‘indicators
of reasonableness” like the ‘‘total time index” Ti = (sum
of dwell time  source strength)/(PD  number of dwell
positions) [59] that should be of the same order for
implants of comparable geometry.
- If possible, a recalculation with a second independent ver-
ification system is favored.2. Plan data transfer
- After export of the treatment plan to the control unit of
the afterloader, the correctness of the transferred param-
eters including patient data, prescribed dose, fractiona-
tion, source drive-out length, total and individual source
dwell times should be verified.
3. Connection of catheters with transfer tubes
- Correct labelling and numbering of the catheters must be
verified.
- A photograph of the connecting end of the catheters taken
before the start of treatment planning is recommended to
verify the numbering. The correct labelling of the individ-
ual catheters should be checked by a second person.
- If the catheters are cut individually to a specific internal
length, prior to starting treatment, the length should be
checked by a second person.
- Connecting the catheters to transfer tubes: Even if the
tubes themselves are numbered, they might get mixed
up. Therefore, it is recommended not to rely on the tube
number only but to follow the course of each transfer
tube from the afterloader’s indexer to the corresponding
catheter.
- Make sure that the catheters are in the correct position in
the breast and the fixation buttons are in contact with the
skin surface.
- Make sure that during imaging and treatment identical
patient positioning is guaranteed, to ensure the same
anatomical positions of the organs.
4. Final control before initiation of irradiation
- The total length (transfer tube with catheter) should be
checked (with a marked wire or special manufacturer’s
tools like ‘‘source position simulator”).
- A test run with a check cable should be performed for all
catheters prior to drive-out of the source to verify the
proper connection and to eliminate catheter obstruction.
Perioperative and post-implantation care
Perioperative care: The insertion of catheters should be per-
formed under sterile conditions. Special care should be taken toPlease cite this article in press as: Strnad V et al. ESTRO-ACROP guideline: Int
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Post-implantation care: While the patient is receiving radiation
therapy check that the buttons are not pressing on the skin too
hard while not being too loose to avoid ulceration and the develop-
ment of chronic skin marks, such as acromia or skin necrosis, in the
future. Although use of antibiotics is not mandatory in some cen-
tres, a pre-implantation single-shot antibiosis, for example with
Ampicillin/Sulbactam iv 1 3 g, is standard in others. Here, ade-
quate rules according to the corresponding surgical discipline of
each centre should be adhered to.
It goes without saying that a responsible physician will perform
a daily ward round to rule out signs of breast infection and to
detect possible changes in breast volume (may indicate develop-
ment of haematoma). In case of apparent or suspected changes
in the breast volume or the position of plastic catheters a verifica-
tion of these findings by CT must be done and if necessary planning
issues taken into consideration.Conclusion
Early breast carcinoma after BCT can be treated with radiation
therapy with a very limited volume of irradiated tissue and APBI
has become a standard postoperative treatment modality. Postop-
erative APBI with multi-catheter-brachytherapy for selected
patients with early breast cancer to date is the only radio-
oncological treatment method with duration of only 4–5 days for
which there is level 1 evidence [1,4,60]. In addition to appropriate
patient selection [13] and target definition [14,15,61], we consider
that practical issues like the method of catheter insertion, dose
optimization and quality assurance are of great importance and
need to be standardized. The technical aspects and QA have until
now been discussed only marginally in some US guidelines
[17,62] and no European guidelines are available at the moment.
The current guideline finally fills this gap and is intended to pro-
mote the safe and efficient delivery of APBI with image-guided
multi-catheter brachytherapy. It is based on the current practice
of APBI in Europe as reviewed from clinical trials, published litera-
ture, and prior clinical experience of panel experts. This guideline
was developed as a consensus-based statement and has been
reviewed and approved by the board of the GEC-ESTRO and ACROP.
The aim is to assure a standard quality level during the procedure
of implantation, definition of the CTV and treatment with multi-
catheter brachytherapy in breast carcinoma.
We hope that the present guideline can be viewed as an impor-
tant aid to radiation oncologists in managing patients with early
breast cancer. Interstitial multi-catheter brachytherapy has been
used for many years, therefore diverse techniques have been devel-
oped, and outcome data prove that they are adequate to offer an
improved breast cancer control without severe acute and late
effects. The practitioner’s experience is useful, but only if there is
a recording of data and an appraisal of long-term results.
The panel of experts also recommends that the radiation oncol-
ogists and the medical physicists at a facility introducing APBI with
multi-catheter image-guided brachytherapy for the treatment of
patients with early breast cancer attend courses designed to
review APBI practice and QM and spend an adequate amount of
time learning the procedure at a facility with extensive experience
in APBI using brachytherapy.
In summary it can be stated that the presented guidelines make
it possible to assure the best possible quality and accuracy of
image-guided breast brachytherapy as well as adequate dose cov-
erage of the target volume inside the breast with appropriate qual-
ity of the dosimetry, in order to achieve optimum long-termerstitial multi-catheter breast brachytherapy as Accelerated Partial Breast
tical recommendations. Radiother Oncol (2018), https://doi.org/10.1016/j.
V. Strnad et al. / Radiotherapy and Oncology xxx (2018) xxx–xxx 9results. The same rules should be used for the boost with multi-
catheter brachytherapy after WBI and for APBrI.
Conflict of interest statement
None declared.
Financial disclosure statement
Neither author has any funding sources; no funding sources
were used in conjunction with this manuscript.
Disclaimer
ESTRO cannot endorse all statements or opinions made on the
guidelines. Regardless of the vast professional knowledge and sci-
entific expertise in the field of radiation oncology that ESTRO pos-
sesses, the Society cannot inspect all information to determine the
truthfulness, accuracy, reliability, completeness or relevancy
thereof. Under no circumstances will ESTRO be held liable for
any decision taken or acted upon as a result of reliance on the con-
tent of the guidelines.
The component information of the guidelines is not intended or
implied to be a substitute for professional medical advice or med-
ical care. The advice of a medical professional should always be
sought prior to commencing any form of medical treatment. To this
end, all component information contained within the guidelines is
done so for solely educational and scientific purposes. ESTRO and
all of its staff, agents and members disclaim any and all warranties
and representations with regard to the information contained on
the guidelines. This includes any implied warranties and condi-
tions that may be derived from the aforementioned guidelines.
Acknowledgements
The authors acknowledge Cynthia Aristei (Radiation Oncology
Section, University of Perugia and Perugia General Hospital, Italy)
for her detailed suggestions. Furthermore we wish to thank Philip
Poortmans (Department of Radiation Oncology, Institut Curie,
Paris, France), Frank-André Siebert (Clinic of Radiotherapy, Univer-
sity Hospital of Schleswig-Holstein, Kiel, Germany), and Ferran
Guedea (Department of Radiation Oncology, Institut Català
d’Oncologia, University of Barcelona, L’Hospitalet del Llobregat,
Barcelona, Spain) for stimulating comments during preparation of
this recommendation.
References
[1] Strnad V, Ott OJ, Hildebrandt G, Kauer-Dorner D, Knauerhase H, Major T, et al.
5-year results of accelerated partial breast irradiation using sole interstitial
multicatheter brachytherapy versus whole-breast irradiation with boost after
breast-conserving surgery for low-risk invasive and in-situ carcinoma of the
female breast: a randomised, phase 3, non-inferiority trial. Lancet
2016;387:229–38.
[2] Hannoun-Levi JM, Resch A, Gal J, Kauer-Dorner D, Strnad V, Niehoff P, et al.
Accelerated partial breast irradiation with interstitial brachytherapy as second
conservative treatment for ipsilateral breast tumour recurrence: multicentric
study of the GEC-ESTRO Breast Cancer Working Group. Radiother Oncol
2013;108:226–31.
[3] Guinot JL, Baixauli-Perez C, Soler P, Tortajada MI, Moreno A, Santos MA, et al.
High-dose-rate brachytherapy boost effect on local tumor control in young
women with breast cancer. Int J Radiat Oncol Biol Phys 2015;91:165–71.
[4] Polgar C, Ott OJ, Hildebrandt G, Kauer-Dorner D, Knauerhase H, Major T, et al.
Late side-effects and cosmetic results of accelerated partial breast irradiation
with interstitial brachytherapy versus whole-breast irradiation after breast-
conserving surgery for low-risk invasive and in-situ carcinoma of the female
breast: 5-year results of a randomised, controlled, phase 3 trial. Lancet Oncol
2017;18:259–68.
[5] Lettmaier S, Kreppner S, Lotter M, Walser M, Ott OJ, Fietkau R, et al. Radiation
exposure of the heart, lung and skin by radiation therapy for breast cancer: a
dosimetric comparison between partial breast irradiation using multicatheterPlease cite this article in press as: Strnad V et al. ESTRO-ACROP guideline: Int
Irradiation alone or as boost – GEC-ESTRO Breast Cancer Working Group prac
radonc.2018.04.009brachytherapy and whole breast teletherapy. Radiother Oncol
2011;100:189–94.
[6] Major T, Gutierrez C, Guix B, Mozsa E, Hannoun-Levi JM, Lossl K, et al.
Interobserver variations of target volume delineation in multicatheter partial
breast brachytherapy after open cavity surgery. Brachytherapy
2015;14:925–32.
[7] Ott OJ, Schulz-Wendtland R, UterW, Pfahlberg A, BeckmannMW, Sauer R, et al.
Fat necrosis after conserving surgery and interstitial brachytherapy and/or
external-beam irradiation in women with breast cancer. Strahlenther Onkol
2005;181:638–44.
[8] Ott OJ, Hildebrandt G, Potter R, Hammer J, Lotter M, Resch A, et al. Accelerated
partial breast irradiation with multi-catheter brachytherapy: Local control,
side effects and cosmetic outcome for 274 patients. Results of the German-
Austrian multi-centre trial. Radiother Oncol 2007;82:281–6.
[9] Strnad V, Hildebrandt G, Potter R, Hammer J, Hindemith M, Resch A, et al.
Accelerated partial breast irradiation: 5-year results of the German-Austrian
multicenter phase II trial using interstitial multicatheter brachytherapy alone
after breast-conserving surgery. Int J Radiat Oncol Biol Phys 2011;80:17–24.
[10] Polgar C, Major T, Fodor J, Sulyok Z, Somogyi A, Lovey K, et al. Accelerated
partial-breast irradiation using high-dose-rate interstitial brachytherapy: 12-
year update of a prospective clinical study. Radiother Oncol 2010;94:274–9.
[11] Polgar C, Fodor J, Major T, Sulyok Z, Kasler M. Breast-conserving therapy with
partial or whole breast irradiation: Ten-year results of the Budapest
randomized trial. Radiother Oncol 2013;108:197–202.
[12] Aristei C, Maranzano E, Lancellotta V, Chirico L, Zucchetti C, Italiani M, et al.
Partial breast irradiation with interstitial multi-catheter high-dose-rate
brachytherapy. Long-term results of a phase II prospective study. Radiother
Oncol 2017.
[13] Polgar C, Van Limbergen E, Potter R, Kovacs G, Polo A, Lyczek J, et al. Patient
selection for accelerated partial-breast irradiation (APBI) after breast-
conserving surgery: recommendations of the Groupe Europeen de
Curietherapie-European Society for Therapeutic Radiology and Oncology
(GEC-ESTRO) breast cancer working group based on clinical evidence (2009).
Radiother Oncol 2010;94:264–73.
[14] Strnad V, Hannoun-Levi JM, Guinot JL, Lossl K, Kauer-Dorner D, Resch A, et al.
Recommendations from GEC ESTRO Breast Cancer Working Group (I): Target
definition and target delineation for accelerated or boost Partial Breast
Irradiation using multicatheter interstitial brachytherapy after breast
conserving closed cavity surgery. Radiother Oncol 2015;115:342–8.
[15] Major T, Gutierrez C, Guix B, van Limbergen E, Strnad V, Polgar C, et al.
Recommendations from GEC ESTRO Breast Cancer Working Group (II): Target
definition and target delineation for accelerated or boost partial breast
irradiation using multicatheter interstitial brachytherapy after breast
conserving open cavity surgery. Radiother Oncol 2016;118:199–204.
[16] Correa C, Harris EE, Leonardi MC, Smith BD, Taghian AG, Thompson AM, et al.
Accelerated Partial Breast Irradiation: Executive summary for the update of an
ASTRO Evidence-Based Consensus Statement. Pract Radiat Oncol 2016.
[17] Shah C, Vicini F, Wazer DE, Arthur D, Patel RR. The American Brachytherapy
Society consensus statement for accelerated partial breast irradiation.
Brachytherapy. 2013;12:267–77.
[18] Smith BD, Arthur DW, Buchholz TA, Haffty BG, Hahn CA, Hardenbergh PH, et al.
Accelerated partial breast irradiation consensus statement from the American
Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys
2009;74:987–1001.
[19] Vicini F WJ, Arthur D, et al. NSABP Protocol B39/RTOG Protocol 0413: A
randomized phase III study of conventional whole breast irradiation versus
partial breast irradiation for women with stage 0.I, or II breast cancer. National
Surgical Adjuvant Breast and Bowel Project/Radiation Therapy Oncology
Group, Pittsburgh/Philadelphia; 2004. http://atc.wustl.edu/protocols/nsabp/
b-39/0413.pdf, Accessed 26 April, 2017.
[20] Huang J, Barbera L, Brouwers M, Browman G, Mackillop WJ. Does delay in
starting treatment affect the outcomes of radiotherapy? A systematic review. J
Clin Oncol 2003;21:555–63.
[21] Recht A, Come SE, Gelman RS, Goldstein M, Tishler S, Gore SM, et al.
Integration of conservative surgery, radiotherapy, and chemotherapy for the
treatment of early-stage, node-positive breast cancer: sequencing, timing, and
outcome. J Clin Oncol 1991;9:1662–7.
[22] Hebert-Croteau N, Freeman CR, Latreille J, Brisson J. Delay in adjuvant
radiation treatment and outcomes of breast cancer–a review. Breast Cancer
Res Treat 2002;74:77–94.
[23] Froud PJ, Mates D, Jackson JS, Phillips N, Andersen S, Jackson SM, et al.
Effect of time interval between breast-conserving surgery and radiation
therapy on ipsilateral breast recurrence. Int J Radiat Oncol Biol Phys
2000;46:363–72.
[24] Nixon AJ, Recht A, Neuberg D, Connolly JL, Schnitt S, Abner A, et al. The relation
between the surgery-radiotherapy interval and treatment outcome in patients
treated with breast-conserving surgery and radiation therapy without
systemic therapy. Int J Radiat Oncol Biol Phys 1994;30:17–21.
[25] Olivotto IA, Lesperance ML, Truong PT, Nichol A, Berrang T, Tyldesley S, et al.
Intervals longer than 20 weeks from breast-conserving surgery to radiation
therapy are associated with inferior outcome for women with early-stage
breast cancer who are not receiving chemotherapy. J Clin Oncol
2009;27:16–23.
[26] Mikeljevic JS, Haward R, Johnston C, Crellin A, Dodwell D, Jones A, et al. Trends
in postoperative radiotherapy delay and the effect on survival in breast cancer
patients treated with conservation surgery. Br J Cancer 2004;90:1343–8.erstitial multi-catheter breast brachytherapy as Accelerated Partial Breast
tical recommendations. Radiother Oncol (2018), https://doi.org/10.1016/j.
10 ESTRO-ACROP practical guideline[27] Cefaro GA, Genovesi D, Marchese R, Di Tommaso M, Di Febo F, Ballone E, et al.
The effect of delaying adjuvant radiation treatment after conservative surgery
for early breast cancer. Breast J 2007;13:575–80.
[28] van Maaren MC, Bretveld RW, Jobsen JJ, Veenstra RK, Groothuis-Oudshoorn
CG, Struikmans H, et al. The influence of timing of radiation therapy following
breast-conserving surgery on 10-year disease-free survival. Br J Cancer
2017;117:179–88.
[29] Correa C, Harris EE, Leonardi MC, Smith BD, Taghian AG, Thompson AM, et al.
Accelerated Partial Breast Irradiation: Executive summary for the update of an
ASTRO Evidence-Based Consensus Statement. Pract Radiat Oncol 2017;7:73–9.
[30] Livi L, Meattini I, Marrazzo L, Simontacchi G, Pallotta S, Saieva C, et al.
Accelerated partial breast irradiation using intensity-modulated radiotherapy
versus whole breast irradiation: 5-year survival analysis of a phase 3
randomised controlled trial. Eur J Cancer 2015;51:451–63.
[31] Rodriguez N, Sanz X, Dengra J, Foro P, Membrive I, Reig A, et al. Five-year
outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam
radiation therapy to deliver accelerated partial breast irradiation. Int J Radiat
Oncol Biol Phys 2013;87:1051–7.
[32] Vaidya JS, Wenz F, Bulsara M, Tobias JS, Joseph DJ, Keshtgar M, et al. Risk-
adapted targeted intraoperative radiotherapy versus whole-breast
radiotherapy for breast cancer: 5-year results for local control and overall
survival from the TARGIT-A randomised trial. Lancet 2014;383:603–13.
[33] Veronesi U, Orecchia R, Maisonneuve P, Viale G, Rotmensz N, Sangalli C, et al.
Intraoperative radiotherapy versus external radiotherapy for early breast
cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol.
2013;14:1269–77.
[34] Bartelink H, Maingon P, Poortmans P, Weltens C, Fourquet A, Jager J, et al.
Whole-breast irradiation with or without a boost for patients treated with
breast-conserving surgery for early breast cancer: 20-year follow-up of a
randomised phase 3 trial. Lancet Oncol 2015;16:47–56.
[35] Brouwers PJ, van Werkhoven E, Bartelink H, Fourquet A, Lemanski C, van Loon
J, et al. Factors associated with patient-reported cosmetic outcome in the
Young Boost Breast Trial. Radiother Oncol 2016;120:107–13.
[36] Poortmans PM, Arenas M, Livi L. Over-irradiation. Breast 2017;31:295–302.
[37] Polo A, Polgar C, Hannoun-Levi JM, Guinot JL, Gutierrez C, Galalae R, et al. Risk
factors and state-of-the-art indications for boost irradiation in invasive breast
carcinoma. Brachytherapy 2017;16:552–64.
[38] Vrieling C, van Werkhoven E, Maingon P, Poortmans P, Weltens C, Fourquet A,
et al. Prognostic factors for local control in breast cancer after long-term
follow-up in the EORTC boost vs no boost trial: a randomized clinical trial.
JAMA Oncol 2017;3:42–8.
[39] Pierquin B, Wilson JF, Chassagne D. The Paris system. Modern
brachytherapy. Masson Pubklishing USA, Inc.; 1987.
[40] Gutierrez C, Najjari D, Martinez E, Botella S, Eraso A, Pino F, et al. The use of an
interstitial boost in the conservative treatment of breast cancer: how to
perform it routinely in a radiotherapy department. J Contemp Brachytherapy
2015;6:397–403.
[41] Major T, Frohlich G, Lovey K, Fodor J, Polgar C. Dosimetric experience with
accelerated partial breast irradiation using image-guided interstitial
brachytherapy. Radiother Oncol 2009;90:48–55.
[42] Polgar C, Strnad V, Major T. Brachytherapy for partial breast irradiation: the
European experience. Semin Radiat Oncol 2005;15:116–22.
[43] Guinot JL, Tortajada MI, Carrascosa M, Crispin V, Otero A, Rios B, et al. Ten-year
results of a phase II study with a single fraction of high-dose-rate
brachytherapy (FAST-boost) after whole breast irradiation in invasive breast
carcinoma. Clin Transl Oncol 2012;14:109–15.
[44] Guinot JL, Roldan S, Maronas M, Tortajada I, Carrascosa M, Chust ML, et al.
Breast-conservative surgery with close or positive margins: can the breast be
preserved with high-dose-rate brachytherapy boost? Int J Radiat Oncol Biol
Phys 2007;68:1381–7.
[45] Resch A, Potter R, Van Limbergen E, Biber E, Klein T, Fellner C, et al. Long-term
results (10 years) of intensive breast conserving therapy including a high-dose
and large-volume interstitial brachytherapy boost (LDR/HDR) for T1/T2 breast
cancer. Radiother Oncol 2002;63:47–58.Please cite this article in press as: Strnad V et al. ESTRO-ACROP guideline: Int
Irradiation alone or as boost – GEC-ESTRO Breast Cancer Working Group prac
radonc.2018.04.009[46] Potter R, Haie-Meder C, Van Limbergen E, Barillot I, De Brabandere M,
Dimopoulos J, et al. Recommendations from gynaecological (GYN) GEC ESTRO
working group (II): concepts and terms in 3D image-based treatment planning
in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D
image-based anatomy, radiation physics, radiobiology. Radiother Oncol
2006;78:67–77.
[47] Viswanathan AN, Beriwal S, De Los Santos JF, Demanes DJ, Gaffney D, Hansen J,
et al. American Brachytherapy Society consensus guidelines for locally
advanced carcinoma of the cervix. Part II: high-dose-rate brachytherapy.
Brachytherapy 2012;11:47–52.
[48] Wang JZ, Li XA, Yu CX, DiBiase SJ. The low alpha/beta ratio for prostate cancer:
what does the clinical outcome of HDR brachytherapy tell us? Int J Radiat
Oncol Biol Phys 2003;57:1101–8.
[49] King CR. LDR vs. HDR brachytherapy for localized prostate cancer: the view
from radiobiological models. Brachytherapy 2002;1:219–26.
[50] Lahmer G, Lotter M, Kreppner S, Fietkau R, Strnad V. Protocol-based image-
guided salvage brachytherapy Early results in patients with local failure of
prostate cancer after radiation therapy. Strahlentherapie Und Onkologie
2013;189:668–74.
[51] Baltas D, Kolotas C, Geramani K, Mould RF, Ioannidis G, Kekchidi M, et al. A
conformal index (COIN) to evaluate implant quality and dose specification in
brachytherapy. Int J Radiat Oncol Biol Phys 1998;40:515–24.
[52] Hilts M, Halperin H, Morton D, Batchelar D, Bachand F, Chowdhury R, et al.
Skin dose in breast brachytherapy: Defining a robust metric. Brachytherapy
2015;14:970–8.
[53] Genebes C, Chand ME, Gal J, Gautier M, Raoust I, Ihrai T, et al. Accelerated
partial breast irradiation in the elderly: 5-year results of high-dose rate multi-
catheter brachytherapy. Radiat Oncol 2014;9:115.
[54] Wazer DE, Kaufman S, Cuttino L, DiPetrillo T, Arthur DW. Accelerated partial
breast irradiation: an analysis of variables associated with late toxicity and
long-term cosmetic outcome after high-dose-rate interstitial brachytherapy.
Int J Radiat Oncol Biol Phys 2006;64:489–95.
[55] Garsa AA, Ferraro DJ, DeWees TA, Deshields TL, Margenthaler JA, Cyr AE, et al. A
prospective longitudinal clinical trial evaluating quality of life after breast-
conserving surgery and high-dose-rate interstitial brachytherapy for early-
stage breast cancer. Int J Radiat Oncol Biol Phys 2013;87:1043–50.
[56] Strnad V PC. Phase III Multicenter Trial: Interstitial brachytherapy alone versus
external beam radiation therapy after breast conserving surgery for low risk
invasive carcinoma and low risk duct carcinoma in situ (DCIS) of the female
breast. Study Protocol, European Brachytherapy Breast Cancer GEC-ESTRO
Working Group. http://www.apbi.uni-erlangen.de/outline/outline.html,
Accessed 26 April, 2017.
[57] Garsa AA, Ferraro DJ, DeWees T, Margenthaler JA, Naughton M, Aft R, et al.
Analysis of fat necrosis after adjuvant high-dose-rate interstitial
brachytherapy for early stage breast cancer. Brachytherapy 2013;12:99–106.
[58] Kirisits C, Rivard MJ, Baltas D, Ballester F, De Brabandere M, van der Laarse R,
et al. Review of clinical brachytherapy uncertainties: analysis guidelines of
GEC-ESTRO and the AAPM. Radiother Oncol 2014;110:199–212.
[59] Thomadsen B. Achieving quality in brachytherapy. IOP Publishing Ltd; 2000. p.
126–60.
[60] Ott OJ, Strnad V, Hildebrandt G, Kauer-Dorner D, Knauerhase H, Major T, et al.
GEC-ESTRO multicenter phase 3-trial: Accelerated partial breast irradiation
with interstitial multicatheter brachytherapy versus external beam whole
breast irradiation: Early toxicity and patient compliance. Radiother Oncol
2016;120:119–23.
[61] Roth AM, Kauer-Dorner D, Resch A, Schmid A, Thill M, Niehoff P, et al. Is
oncoplastic surgery a contraindication for accelerated partial breast radiation
using the interstitial multicatheter brachytherapy method? Brachytherapy
2014;13:394–9.
[62] Hepel JT, Arthur D, Shaitelman S, Polgar C, Todor D, Zoberi I, et al. American
Brachytherapy Society consensus report for accelerated partial breast
irradiation using interstitial multicatheter brachytherapy. Brachytherapy
2017;16:919–28.erstitial multi-catheter breast brachytherapy as Accelerated Partial Breast
tical recommendations. Radiother Oncol (2018), https://doi.org/10.1016/j.
